Teva- Pharmaceutical Industries Ltd ADR Dossier
|
SectorHealth Care IndustryPharmaceuticals Beta (adjusted)0.92 Intrinsic Value $14.26median of 6 methods · middle span $13-$15based on filings through 30 Jun 2026 Market Price $39.60Price as of 30 Sep 2026 Significantly overvaluedIntrinsic value is 64% below the market price −50% · IV below pricenear fair value ±15%IV above price · +50% marker beyond scale (-64%) Data confidence Sign in to view data confidence Market Cap $46.2B Enterprise Value $47B Shares Outstanding 1.2B diluted Moat Rating Wide Next Earnings Date3 Nov 2026 Last ex-dividend27 Nov 2017 All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference. ThesisStreet consensus, scenarios, merits, risks, and invalidation triggers Thesis Summary Teva's investment case is balanced. Its three key innovative brands grew 43% year over year in local currency during Q2 2026, management raised each brand's 2026 outlook, and ecopipam received FDA Priority Review after positive Phase 3 evidence. These developments support a continued shift toward innovative medicines. Offsetting them, global generics revenue declined 15% in local currency, major pipeline assets remain subject to regulatory and commercialization risk, and execution of the transformation remains essential. Moody's August 2026 upgrade to investment grade strengthens the qualitative case. This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today. Street view · analyst 12-month targets Low · most bearish analyst$33.00 Mean target$41.40 High · most bullish analyst$50.00 Street targets sit above today's price; our intrinsic value sits below it. Different horizons, different questions. Our research · scenarios, merits, risks, and invalidation triggersResearch as of 2 Sep 2026 Scenarios · 12-month scenario targets Bear CaseDownside scenario $33.0020% Innovative-brand growth decelerates materially, generics pressure persists, or regulatory and launch delays affect olanzapine LAI or ecopipam. Under this scenario, the innovative portfolio does not offset erosion in mature products quickly enough to sustain the expected transformation. Base CaseCentral scenario $41.4050% Matches the consensus meanInnovative-brand momentum continues but moderates toward management's full-year outlook, partly offsetting pressure in generics. Olanzapine LAI and ecopipam progress broadly on schedule, while regulatory and launch execution remain material uncertainties. Bull CaseUpside scenario $50.0030% AUSTEDO, AJOVY and UZEDY sustain strong growth; olanzapine LAI launches in the United States during Q4 2026; ecopipam progresses through Priority Review; and duvakitug recruitment remains on track. Successful execution would accelerate Teva's innovative-product mix and strengthen confidence in its post-2027 pipeline. Scenarios are anchored to street consensus at the research date, with our probabilities and rationale. Key Investment Merits
Key Investment Risks
All scenarios are estimates and subject to change. Past performance is not indicative of future results. Quality Pillars MembersThis section is available to registered members. Create a free account or sign in to unlock the full breakdown. Explore this dossierValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework. |